Project Grant R37CA293214
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$439K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
The National Cancer Institute (NCI), through its federal grant program "Cancer Cause and Prevention Research" (CFDA 93.393), awarded a 4-year, $2,136,715 Project Grant to the President and Fellows of Harvard College, Harvard T.H. Chan School of Public Health, to conduct research on "Harnessing DNA Methylation in Peripheral Blood for Improved Colorectal Cancer Prevention". The project aims to leverage DNA methylation analysis in blood samples to develop new strategies for...
The National Cancer Institute (NCI) awarded a $551,848 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant supports a 5-year research project to investigate the molecular mechanisms by which the transcription factor SOX9 impairs differentiation and promotes developmental reprogramming in colorectal cancer (CRC). The key objectives are to: 1) apply unbiased analyses to identify regulators of...
This $640,583 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (mCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells, which can boost the metabolic fitness and anti-tumor activity of these immune cells within the mCRC tumor microenvironment. The research will investigate the specific mechanisms by which PPARD activation...
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...
The National Cancer Institute (NCI) awarded a $205,700 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer. The research aims to explore a novel combination approach of DNA repair inhibition and targeted therapy to prevent the emergence of resistance. Through analysis of clinical samples, cell lines, and...
This $399,187 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by Virginia Commonwealth University (VCU) to determine the role of ATG16L1 isoforms in colorectal cancer (CRC) tumor growth, metastasis, and treatment response. The research aims to 1) assess how ATG16L1 T300T and A300A isoforms impact CRC tumor progression in mouse models, and 2) evaluate whether the T300T isoform predicts...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $107,071 to Rockefeller University from March 1, 2025 to February 28, 2029. The grant supports research to investigate the role of endoplasmic reticulum-mitochondria contact sites (ERMCS) in metabolic adaptation and survival of colorectal cancer cells, particularly under hypoxic tumor microenvironments. The research aims to identify the...
This $546,625 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a new immunochemotherapy approach for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award include: Developing and characterizing a novel nanoparticle carrier system that can co-deliver small interfering RNA (siRNA) targeting the IRHOM1 protein and a chemotherapeutic agent...
The National Cancer Institute (NCI) awarded a $600,499 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of Columbia University in the City of New York, Health Sciences Division. The 5-year project, awarded on April 1, 2025, aims to investigate the role of the bacterium Fusobacterium nucleatum (FN) and the protein Annexin A1 (ANXA1) as potential biomarkers in colorectal cancer oncogenesis. Specifically, the research will: (I) examine the mechanistic and...
This $627,422 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a first-of-its-kind intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The award to the Regents of the University of Michigan will fund research to engineer commensal E. coli bacteria to display the anti-toxin enzyme ColBs, which can neutralize the colibactin genotoxin and prevent associated DNA damage and tumorigenesis. Key...